FGF19-FGFR4 Signaling in Hepatocellular Carcinoma
- Authors
- Raja, Aroosha; Park, Inkeun; Haq, Farhan; Ahn, Sung-Min
- Issue Date
- Jun-2019
- Publisher
- MDPI
- Keywords
- prognosis; FGF19; FGFR4; HCC; inhibitors
- Citation
- CELLS, v.8, no.6
- Journal Title
- CELLS
- Volume
- 8
- Number
- 6
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/1450
- DOI
- 10.3390/cells8060536
- ISSN
- 2073-4409
- Abstract
- Hepatocellular carcinoma (HCC) is the sixth most common type of cancer, with an increasing mortality rate. Aberrant expression of fibroblast growth factor 19-fibroblast growth factor receptor 4 (FGF19-FGFR4) is reported to be an oncogenic-driver pathway for HCC patients. Thus, the FGF19-FGFR4 signaling pathway is a promising target for the treatment of HCC. Several pan-FGFR (1-4) and FGFR4-specific inhibitors are in different phases of clinical trials. In this review, we summarize the information, recent developments, binding modes, selectivity, and clinical trial phases of different available FGFR4/pan-FGF inhibitors. We also discuss future perspectives and highlight the points that should be addressed to improve the efficacy of these inhibitors.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의예과 > 1. Journal Articles
- 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/1450)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.